免疫检查点抑制剂联合放疗在晚期非小细胞肺癌的研究进展
摘要
并改变了晚期非小细胞肺癌（non-samll cell llung cancer，NSCLC）治疗的模式，但免疫单药治疗的获益人群
有限。放疗 (radiotherapy，RT) 作为局部治疗因其耐受性较好、效果显著等特点广泛应用于癌症患者的治疗。
有研究发现放疗可以通过提高肿瘤免疫原性、重塑肿瘤免疫微环境的途径激活抗肿瘤免疫。目前，越来越多
的证据表明 RT 和 ICIs 之间存在协同作用。如何充分发挥放疗联合免疫治疗（immunotherapy combined with
radiotherapy，iRT）的协同作用，提高晚期非小细胞肺癌患者的治疗效果 , 带来良好的预后 , 是肿瘤治疗领域亟
待解决的热点问题。本文将对 iRT 在晚期 NSCLC 中的作用机制及临床研究进展等方面进行综述，为未来临床
iRT 的选择提供参考。
关键词
全文:
PDF参考
[1]Sung H, Ferlay J, Siegel RL, et al. Global Cancer
Statistics 2020: GLOBOCAN Estimates of Incidence and
Mortality Worldwide for 36 Cancers in 185 Countries[J].
CA Cancer J Clin, 2021, 71(3): 209-249.
[2]Galluzzi L, Chan TA, Kroemer G, etal. The
hallmarks of successful anticancer immunotherapy. Sci
Transl Med. 2018 Sep 19;10(459):eaat7807. doi: 10.1126/
scitranslmed.aat7807. PMID: 30232229.
[3]Zhang Z, Liu X, Chen D, Yu J. Radiotherapy
combined with immunotherapy: the dawn of cancer
treatment. Signal Transduct Target Ther. 2022 Jul
29;7(1):258. doi: 10.1038/s41392-022-01102-y. PMID:
35906199; PMCID: PMC9338328.
[4]Dillon MT, Bergerhoff KF, Pedersen M, et al. Clin
Cancer Res. 2019 Jun 1;25(11):3392-3403.
[5]Xia WY, Feng W, Zhang CC, et al. Radiotherapy
for non-small cell lung cancer in the immunotherapy era:
the opportunity and challenge-a narrative review. Transl
Lung Cancer Res. 2020 Oct;9(5):2120-2136.
[6]Galluzzi L, Vanpouille-Box C, Bakhoum SF,et
al. SnapShot: CGAS-STING Signaling. Cell. 2018 Mar
22;173(1):276-276.e1.
[7]Rodríguez-Ruiz ME, Vanpouille-Box C,
Melero I, et al. Immunological Mechanisms Responsible
for Radiation-Induced Abscopal Effect. Trends Immunol.
2018 Aug;39(8):644-655.
[8]Dong Y, Wan Z, Gao X, et al. Reprogramming
Immune Cells for Enhanced Cancer Immunotherapy:
Targets and Strategies. Front Immunol. 2021 Apr
21;12:609762.
[9]Shang S, Liu J, Verma V, et al. Combined
treatment of non-small cell lung cancer using radiotherapy
and immunotherapy: challenges and updates. Cancer
Commun (Lond). 2021 Nov;41(11):1086-1099.
[10]Faivre-Finn C, Vicente D, Kurata T, et al FourYear Survival With Durvalumab After Chemoradiotherapy
in Stage III NSCLC-an Update From the PACIFIC Trial.
J Thorac Oncol. 2021 May;16(5):860-867.
[11]Shang S, Liu J, Verma V, et al. Combined
treatment of non-small cell lung cancer using radiotherapy
and immunotherapy: challenges and updates. Cancer
Commun (Lond). 2021 Nov;41(11):1086-1099.
[12]Geng Y, Zhang Q, Feng S, et al. Safety and
Efficacy of PD-1/PD-L1 inhibitors combined with
radiotherapy in patients with non-small-cell lung cancer:
a systematic review and meta-analysis. Cancer Med. 2021
Feb;10(4):1222-1239.
[13]Lin SH, Lin Y, Yao L, et al. Phase II Trial of
Concurrent Atezolizumab With Chemoradiation for
Unresectable NSCLC. J Thorac Oncol 2020;15:248-57.
[14]Hwang WL, Niemierko A, Hwang KL, et al.
Clinical Outcomes in Patients With Metastatic Lung
Cancer Treated With PD-1/PD-L1 Inhibitors and
Thoracic Radiotherapy. JAMA Oncol 2018;4:253-5.
(22 摘要 Views, 34 PDF Downloads)
Refbacks
- 当前没有refback。